Skip to main content

Table 1 Baseline characteristics of 90 patients with TNBC by NLR

From: Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients

Characteristics

Total (n = 90)

NLR ≤3 (n = 73)

NLR > 3 (n = 17)

p-value

Age

    

  ≤50 years

41 (45.5)

35 (38.8)

6 (6.7)

0.17

  >50 years

49 (54.5)

38 (42.3)

11 (12.2)

Performance status

    

  ECOG 0

70 (77.7)

62 (68,8)

8 (8.9)

0.37

  ECOG 1

20 (22.3)

11 (12.3)

9 (10.0)

Menopausal status

    

  Pre-

36 (40.0)

31 (34.4)

5 (5.6)

0.44

  Post-

54 (60.0)

42 (46.7)

12 (13.3)

Tumour size

    

  pT1

52 (57.7)

45 (49.9)

7 (7.8)

0.56

  pT2

37 (41.1)

27 (30.0)

10 (11.1)

  pT3

1 (1.2)

1 (1.2)

0 (0)

Lymph node status (pN)

    

  pN0

52 (57.7)

42 (46.6)

10 (11.1)

0.44

  pN1

28 (31.2)

24 (26.7)

4 (4.5)

  pN2

10 (11.1)

7 (7.8)

3 (3,3)

Stage*

    

  I

33 (36.7)

29 (32.2)

4 (4.5)

0.39

  II

48 (53.3)

38 (42.2)

10 (11.1)

  IIIA

9 (10.0)

6 (6.7)

3 (3.3)

Tumour histology

    

  Ductal carcinoma

82 (91.1)

69 (76.7)

13 (14.4)

0.29

  Lobular carcinoma

1 (1.2)

0 (0)

1 (1.2)

  Other

7 (7.7)

4 (4.4)

3 (3.3)

Histologic grade

    

  I-II

9 (10.0)

7 (7.8)

2 (2.2)

0.84

  III

81 (90.0)

66 (73.3)

15 (16.7)

Ki-67

    

  ≤20%

15 (16.6)

13 (14.4)

2 (2.2)

0.79

  >20%

75 (83.4)

60 (66.7)

15 (16.7)

Lympho-vascular invasion

    

  Yes

14 (15.6)

7 (7.8)

7 (7.8)

0.07

  No

76 (84.4)

66 (73.3)

10 (11.1)

Necrosis

    

  Yes

15 (16.6)

11 (12.1)

4 (4.5)

0.89

  No

75 (83.4)

62 (69.0)

13 (14.4)

Type of surgery

    

  Quadrantectomy

71 (77.9)

60 (65.7)

11 (12.2)

0.75

  Radical mastectomy

19 (22.1)

13 (15.4)

6 (6.7)

Adjuvant chemotherapy

    

  Antracycline containing

48 (53.3)

40 (44.4)

8 (8.9)

0.59

  CMF

40 (44.5)

31 (34.5)

9 (10.0)

  No

2 (2.2)

2 (2.2)

0 (0)

Adjuvant radiotherapy

    

  Yes

71 (77.9)

60 (65.7)

11 (12.2)

0.61

  No

19 (22.1)

13 (15.4)

6 (6.7)

Recurrences

    

  Yes

13 (14.5)

8 (8.9)

5 (5.6)

0.12

  No

77 (85.5)

65 (72.2)

12 (13.3)

Deaths

    

  Yes

8 (8.9)

4 (4.4)

4 (4.5)

0.06

  No

82 (91.1)

69 (76.7)

13 (14.4)

  1. Table 1 shows the lack of significant correlation among pre-treatment NLR and clinical pathological factors.
  2. *AJCC. Cancer Staging manual. Seventh edition. New York, Springer 2009.
  3. Legend: NLR = Neutrophil to Lymphocyte Ratio; TNBC = Triple Negative Breast Cancer.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us